Veracyte, INC

Veracyte, Inc. has acquired Convergent Genomics, bolstering its urology diagnostics portfolio with Convergent's urinary tumor DNA testing platform.

Veracyte, Inc. announced robust second quarter 2026 financial results, exceeding expectations with significant revenue growth, profitability, and the successful launch of two new products.

Veracyte stockholders approved an amendment to the 2023 Equity Incentive Plan, authorizing an additional 3.5 million shares for issuance.

Veracyte, Inc. announced robust first quarter 2026 financial results, with total revenue increasing 21% year-over-year to $139.1 million, driven by strong performance in its Decipher and Afirma tests.

Veracyte, Inc. announced the appointment of Dr. Kevin Haas as its new Chief Development and Technology Officer, effective March 24, 2026.

Veracyte, Inc. announced robust financial results for the fourth quarter and full year ended December 31, 2025, driven by double-digit growth in its core testing business.

Veracyte, Inc. announced its Q2 2026 financial results, showcasing a significant increase in total revenue driven by robust testing revenue, alongside strategic advancements in its diagnostic platforms.

Veracyte, Inc. announced a significant increase in revenue and net income for the first quarter of 2026, driven by strong performance in its testing business.

Veracyte, Inc. reported a significant increase in net income and testing revenue for the third quarter and first nine months of 2025, driven by higher diagnostic test volumes.

Veracyte, Inc. reported a 14% increase in total revenue for the second quarter of 2025, reaching $130.2 million, despite a net loss of $1.0 million primarily due to a $20.5 million asset impairment charge related to its French subsidiary divestiture.

Veracyte's Q1 2025 revenue increased by 18% year-over-year, driven by growth in testing revenue and biopharmaceutical collaborations.

Veracyte's Q3 2024 results show significant growth in testing revenue and a return to profitability, despite some challenges in product and biopharmaceutical revenue.

Veracyte, Inc. reported a significant increase in total revenue and net income for the fiscal year ended December 31, 2025, driven by strong growth in its Decipher Prostate and Afirma tests and strategic expansion into minimal residual disease diagnostics.

Veracyte's 2024 10-K filing highlights revenue growth driven by its Decipher Prostate and Afirma tests, alongside strategic investments in minimal residual disease (MRD) testing and global expansion.

Veracyte's 10-K filing outlines its capital structure, business model, and regulatory environment, highlighting its focus on cancer diagnostics and global expansion.

John Leite, Global Chief Commercial Off of Veracyte, Inc., sold 4,015 shares of common stock on September 21, 2026 for $40.00 per share.

Jens Holstein, a Director of Veracyte, Inc., sold 5,000 shares of common stock on September 14, 2026 for $40.95 per share.

Jonathan Wygant, VP, Chief Accounting Officer of Veracyte, Inc., reported a transaction in 1,361 shares of common stock on September 2, 2026.

John Leite, Global Chief Commercial Off of Veracyte, Inc., reported a transaction in 3,961 shares of common stock on September 2, 2026.

Phillip G. Febbo, Chief Scientific & Med Officer of Veracyte, Inc., sold 13,110 shares of common stock on September 2, 2026.

Rebecca Chambers, Chief Financial Officer of Veracyte, Inc., sold 3,652 shares of common stock on September 2, 2026.

Veracyte, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Veracyte's upcoming annual meeting on June 17, 2025, will address key proposals including director elections, executive compensation, and an amendment to the equity incentive plan.

Veracyte, Inc. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.

Veracyte's 2024 proxy statement outlines proposals for director elections, auditor ratification, executive compensation, and an equity incentive plan amendment, alongside a review of 2023 financial and business achievements.

FMR LLC and Abigail P. Johnson have reported a 10.1% beneficial ownership stake in Veracyte Inc as of May 29, 2026.

Artisan Partners, through its various entities, has reported beneficial ownership of 6.9% of Veracyte, Inc.'s common stock as of March 31, 2026.

State Street Corporation has reported beneficial ownership of 6.3% of Veracyte Inc.'s common stock as of March 31, 2026.

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 9.7% in Veracyte Inc. as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.2% of Veracyte Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 5.67% in Veracyte Inc. common stock as of March 31, 2026.